Prospective, longitudinal, cohort study for assessment of vascular ageing among adults of urban and rural area of Central India: research protocol
Keywords:Cardiovascular risk prediction model, Indian cohort, Validation
Background: Considering the complex interaction of risk factors in causation of CVD; assessment of vascular ageing among the high risk group through non-interventional statistical models was useful in controlling CVD. While, many CVD risk assessment models were especially designed for application in the specific population or region such as SCORE scales for Europeans, ASSIGN scores for people of Scotland. The Framingham Risk Score were modified, validated and used in several countries. Though Indians have significantly higher predilection for CVD, no indigenous scores were developed or validated to assess the CV risk. The objective of the study were to determine vascular age of the study participants using Framingham risk prediction model, to assess its relationship with development of cardiovascular disease and to develop, validate and compare cardiovascular risk prediction model based on the follow up observations of the study participants.
Methods: Community based cohort study will be conducted in large urban and rural population aged 31-60 years of age those who have no evidence of CVD. The study population will be followed up for three years and will be assessed for development of CVD. The vascular age will be determined using Framingham Risk Scores. Based on the risk factors associated with occurrence of CVD during the study period, the risk prediction model will be designed and tested for validity and accuracy.
Results: The newly developed CVD risk prediction will be more accurate in assessment of CV risk among the study subjects.
Conclusions: The newly developed and validated CV risk prediction model specific for Indians may be one of the first prospective CV risk assessment cohort study.
Dantas AP, Jimenez-Altayo F, Vila E. Vascular aging: facts and factors. Front Physiol. 2012;3:325.
Nilsson PM, Nilsson J-Ao, Berglund G. Population-attributable risk of coronary heart disease risk factors during long-term follow-up: the Malmo Preventive Project. J Internal Med. 2006;260:134–41.
Jani B, Rajkumar C. Aging & vascular aging. Postgrad Med J. 2006;82:357–62.
D'Agostino RB, Vasan R, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study, Circulation. 2008;117:743-53.
Matheny M, McPheeters ML, Glasser A, Mercaldo N, Weaver RB, Jerome RN, et al. Systematic Review of Cardiovascular Disease Risk Assessment Tools. Evidence Synthesis No. 85. AHRQ Publication No. 11-05155-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
Vani K. Non-communicable diseases in South-East Asia Region-2011; Situation and response. World Health Organization, New Delhi, 2011.
Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
Selavarajah S, Kaur G, Haniff J, Cheng KC, Hiong TG Graaf Yvd, Bots ML. Comparison of Framingham Risk Score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population. Int J Cardiol. 2014;176(1):211-8.
Brindle PM, McConnachie A, Upton MN, Hart CL, Smith GD, Watt GCM. The accuracy of the Framingham risk-score in different socioeconomic groups:a prospective study. British J General Pract. 2005;55:838-45.
Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal CVD in Europe: SCORE project. Eur Heart J. 2003;24,987–1003.
Ridker PM, Buring JE, Rifai N, Cook NR, Development of CV risk algorithm in women, the Reynolds Risk Score. JAMA. 2007;297(6):611-9.
Assmann G, Cullan P, Schulte H. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation. 2002:105:310-5.
Khot UN, Khot MB, Bajzer CT, Snapp SK, Ohman EM, Brener SJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
Cuende JI, Cuende N, Lagartos JC. How to calculate vascular age with the SCORE project scales:a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31:2351–8.
Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases, Part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104:2855-64.
Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory based versus non-laboratory based methods for assessment of cardiovascular disease risk: the NHANES I Follow-up study cohort. Lancet. 2008;371(9616):923-31.
Chow CK, Joshi R, Celermajer DS, et al. Recalibration of Framingham risk equation for a rural population in India. J Epidemiol Community Health. 2009;63:379-85.
Guha S, Pal SK, Chattarjee N, Guha S, Ghosh A Deb PK. How predictive is the Framingham’s risk prediction algorithm in Indian perspective? A retrospective case-control study from Kolkata. Indian Heart J. 2008;60:330-2.
Jeemon P, Prabhakaran D, Huffman MD, Ramakrishnan L, Goenka S, Thankappan KR. Distribution of 10 year and lifetime predicted risk for cardiovascular disease in the Indian sentinel surveillance study population (Cross-sectional survey results). BMJ Open. 2011;1:e000068.
Lwanga SK, Lemeshow S. Sample size determination in health studies:A Practical Manual: World Health Organization, Geneva:1991.
National Health and Nutrition Examination Survey. Anthropometry Procedures Manual. CDC, Jan. 2007.
National Health and Nutritional Examination Survey III Cycle 2. Pulse and blood pressure procedures for household interviewers. 1989; Westat, Inc. 1650 Research Boulevard, Rockville, MD, 20850.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guidelines for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(17):1809.
Colaguiri S, Aschner A, Beck-Nielsen H, Bennett P, Boulton, Colagiuri R, et al. Global Guidelines for Type 2 Diabetes. (2012) Clinical Guidelines Task Force, Int Diabetes Federation, Brussels, Belgium.
Romdhane HB, Damasceno A, Ebrahim S, Escobar C, Gueyffier F, Jackson R, et. al. Prevention of cardiovascular disease: Guidelines for assessment and management of total cardiovascular risk., WHO Press, World Health organization, 20 Avenue Apia, 1211 Geneva, 2007.